세계의 테라노스틱스 시장 예측(-2028년) : 제품(영상 진단, 방사성 의약품, 바이오마커 스크리닝, 소프트웨어), 용도, 이해관계자별
Theranostics Market by Product (Diagnostic imaging, Radiopharmaceuticals, Biomarker screening, Software), Application, & Stakeholder Expectations - Global Forecast to 2028
상품코드:1420460
리서치사:MarketsandMarkets
발행일:2024년 01월
페이지 정보:영문 194 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
리포트 개요
조사 범위
조사 대상년
2021-2028년
기준년
2022년
예측 기간
2023-2028년
단위
금액(달러)
부문
제품·용도·최종사용자·지역
대상 지역
북미·유럽·아시아태평양·기타 지역
세계의 테라노스틱스 시장 규모는 2023년 21억 달러에서 예측 기간 중 15.5%의 CAGR로 추이하며, 2028년에는 43억 달러 규모로 성장할 것으로 예측됩니다.
R&D 활동의 증가, 임상시험 수의 증가, 정부의 구상 등이 이 시장의 성장에 기여하고 있습니다.
제품별로는 방사성 의약품 부문이 2022년에 최대 점유율을 보이고 있습니다. 이 큰 점유율은 테라노스틱스의 채택이 증가하고 있는 것과 암 등 만성질환의 유병률이 증가하고 있는 것에 기인하고 있습니다.
용도별로는 전립선암 부문이 예측 기간 중 최대의 CAGR을 기록할 것으로 예측됩니다. 암인구의 증가 및 기타 용도에서 테라노스틱스의 이점을 알기 위해 진행중인 임상시험 등의 요인이 시장의 성장을 촉진하고 있습니다.
지역별로는 아시아태평양이 예측 기간 중 최대 성장을 보일 것으로 예측됩니다. 그 주요 이유는 진화하는 헬스케어 인프라와 이 지역에서 주요 기업의 초점 증가입니다. 중국 및 인도 등 신흥 국가의 헬스케어 인프라는 급속한 페이스로 진화하고 있으며, 병원 및 기타 최종사용자에 의한 대규모 투자로 연결되고 있습니다. 이 요인이 이 지역의 시장 성장을 촉진할 것으로 예상되고 있습니다.
세계의 테라노스틱스 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회의 분석, 특허의 동향, 법규제·상환 환경, 사례 연구, 시장 규모의 추이·예측, 각종 구분·지역별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 중요 인사이트
제5장 시장 개요
시장 역학
촉진요인
억제요인
기회
과제
가격 분석
밸류체인 분석
에코시스템/시장 맵
공급망 분석
Porter's Five Forces 분석
규제 상황
테라노스틱스 시장의 타임라인
상환 분석
무역 분석
특허 분석
사례 연구 분석
주요 이해관계자와 구입 기준
주요 컨퍼런스와 이벤트
테라노스틱스 시장의 임상 조사 데이터
제6장 테라노스틱스 시장 : 제품별
영상 진단
방사성 의약품
IVD/바이오마커 스크리닝
소프트웨어 & 서비스
제7장 테라노스틱스 시장 : 용도별
전립선암
골전이
기타 암
기타 용도
제8장 테라노스틱스 시장 : 최종사용자별
병원·암치료 센터
테라노스틱스 센터
연구·학술 센터
제9장 테라노스틱스 시장 : 지역별
북미
유럽
아시아태평양
기타 지역
제10장 경쟁 구도
개요
주요 전략
주요 기업의 채택 전략
매출 점유율 분석
시장 점유율 분석
기업 평가 매트릭스
신규 기업/중소기업 평가 매트릭스
경쟁 시나리오·동향
제11장 기업 개요
주요 기업
ADVANCED ACCELERATOR APPLICATIONS
BAYER AG
GE HEALTHCARE
SIEMENS HEALTHINEERS AG
CARDINAL HEALTH
PHILIPS HEALTHCARE
CANON INC.
CURIUM
LANTHEUS
NORTHSTAR MEDICAL RADIOISOTOPES
ECKERT & ZIEGLER
PHARMALOGIC
ECZACIBASI-MONROL
ACROTECH BIOPHARMA, INC.
기타 기업
THERMO FISHER SCIENTIFIC INC.
GLOBAL MEDICAL SOLUTIONS
SHINE TECHNOLOGIES, LLC
ISOTOPIA MOLECULAR IMAGING LTD.
INSTITUTE OF ISOTOPES
CHINA ISOTOPE & RADIATION CORPORATION
YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
ATOMVIE
ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
TELIX PHARMACEUTICALS LIMITED
BLUE EARTH DIAGNOSTICS
SOFIE BIOSCIENCES
THERAGNOSTICS
제12장 부록
KSA
영문 목차
영문목차
Report Description
Scope of the Report
Years Considered for the Study
2021-2028
Base Year
2022
Forecast Period
2023-2028
Units Considered
Value (USD) Billion
Segments
Product, Application, End user, and Region
Regions covered
North America, Europe, Asia Pacific, Rest of the World
The global theranostics market is projected to reach USD 4.3 billion by 2028 from USD 2.1 billion in 2023, at a CAGR of 15.5% from 2023 to 2028. Factors such as rising baby boomer population and advances in research and development of radiopharmceuticals are responsible for the increasing growth of this market. Increasing research and development activities, rising number of clinical trials, and government initiatives attributes to the growth of theranostics market.
"The radiopharmaceuticals segment held the largest share of the market in 2022."
Based on product, the theranostics market is segmented into diagnostic imaging, radiopharmaceuticals, IVD/biomarker screening, and software and services. The radiopharmaceuticals segment held the largest market share in 2022. The large share of this segment can be attributed to the rising adoption of theranostics and increasing prevalence of chronic diseases such as cancer.
"The prostate cancer application segment is projected to register the highest CAGR of the theranostics market by application during the forecast period."
Based on application, the theranostics market is segmented into prostate cancer, bone metastasis, other cancer, and other applications. The prostate cancer application segment is projected to register the highest CAGR of the theranostics market from 2023 to 2028. Factors such as rising number of cancer population and ongoing clinical trials to know the benefits of theranostics for other applications are driving the market growth.
"The market in the Asia Pacific region is expected to witness the highest growth during the forecast period."
The theranostics market in the APAC region is expected to register the highest CAGR during the forecast period, primarily due to evolving healthcare infrastructure and increasing focus of major players in the region. The healthcare infrastructure in emerging economies, such as China and India is evolving at a rapid pace, leading to major investments by hospitals and other end users. These factors are anticipated to fuel the growth of theranostics market in this region.
A breakdown of the primary participants referred to for this report is provided below:
By Company Type: Tier 1-48%, Tier 2-36%, and Tier 3- 16%
By Designation: Director-level-14%, C-level-10%, and Others-76%
By Region: North America-40%, Europe-32%, Asia Pacific-20%, Rest of the World- 8%
The prominent players in the theranostics market Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US) among others.
Research Coverage
This report studies the theranostics market based on product, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their growth trends and forecasts the revenue of the market segments with respect to three main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall theranostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
Analysis of key drivers (growing geriatric population and rising prevalence of associated diseases, rising use of radiophamrceuticals, rising focus on precision medicine), restraints (short life of radiopharmceuticals, unfavourable reimbursement scenario), opportunities (growth opportunities in emerging countries, advances in research and development of radiopharmceuticals), and challenges (hospital budget cuts and high equipment costs) influencing the growth of the theranostics market
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the theranostics market
Market Development: Comprehensive information about lucrative markets-the report analyses the theranostics market across varied regions
Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the theranostics market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Advanced Accelerator Applications (France), Bayer AG (Germany), GE Healthcare (US).
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SEGMENTATION
1.4.1 MARKETS COVERED
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 RESEARCH LIMITATIONS
1.6 STAKEHOLDERS
1.7 RECESSION IMPACT: THERANOSTICS MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 COMPANY REVENUE ESTIMATION
FIGURE 6 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF BAYER AG
9.3.2.1 Rising geriatric population and increasing number of initiatives for medical isotope development to drive market
TABLE 43 CANADA: KEY MACROINDICATORS
TABLE 44 CANADA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 45 CANADA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
9.4 EUROPE
TABLE 46 EUROPE: THERANOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 47 EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 48 EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 49 EUROPE: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 50 EUROPE: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
9.4.1 EUROPE: RECESSION IMPACT
9.4.2 GERMANY
9.4.2.1 Well-established healthcare system and increased geriatric population to drive market
TABLE 51 GERMANY: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 52 GERMANY: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
9.4.3 UK
9.4.3.1 Increasing government funding in diagnostic imaging to support market growth
TABLE 53 UK: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 54 UK: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
9.4.4 FRANCE
9.4.4.1 Favorable government initiatives and high incidence of cancer to propel market
TABLE 55 FRANCE: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 56 FRANCE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
9.4.5 REST OF EUROPE
TABLE 57 REST OF EUROPE: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 58 REST OF EUROPE: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
9.5 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: CANCER PREVALENCE, 2012-2020
FIGURE 27 ASIA PACIFIC: THERANOSTICS MARKET SNAPSHOT (2022)
TABLE 59 ASIA PACIFIC: THERANOSTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 60 ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 61 ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 63 ASIA PACIFIC: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
9.5.1 ASIA PACIFIC: RECESSION IMPACT
9.5.2 JAPAN
9.5.2.1 Established nuclear medicine infrastructure and better accessibility of healthcare services to drive market
TABLE 64 JAPAN: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 65 JAPAN: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
9.5.3 CHINA
9.5.3.1 Increasing number of government initiatives and growing geriatric population to drive market
TABLE 66 CHINA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 67 CHINA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
9.5.4 INDIA
9.5.4.1 Rising number of nuclear medicine facilities and increasing incidence of chronic diseases to propel market
TABLE 68 INDIA: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 69 INDIA: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
9.5.5 REST OF ASIA PACIFIC
TABLE 70 REST OF ASIA PACIFIC: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 71 REST OF ASIA PACIFIC: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
9.6 REST OF THE WORLD
TABLE 72 REST OF THE WORLD: THERANOSTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
TABLE 73 REST OF THE WORLD: THERANOSTICS MARKET FOR RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION)
TABLE 74 REST OF THE WORLD: THERANOSTICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 75 REST OF THE WORLD: THERANOSTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
9.6.1 REST OF THE WORLD: RECESSION IMPACT
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY STRATEGIES/RIGHT TO WIN
10.3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THERANOSTICS MARKET
FIGURE 28 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN THERANOSTICS MARKET
10.4 REVENUE SHARE ANALYSIS
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP THREE PLAYERS, 2020-2022
10.5 MARKET SHARE ANALYSIS
FIGURE 30 ADVANCED ACCELERATOR APPLICATIONS COMMANDED LARGEST MARKET SHARE IN 2022
TABLE 76 DEGREE OF COMPETITION IN THERANOSTICS MARKET
10.6 COMPANY EVALUATION MATRIX
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
FIGURE 31 COMPANY EVALUATION MATRIX, 2022
10.6.5 COMPANY FOOTPRINT
TABLE 77 PRODUCT AND REGIONAL FOOTPRINT
10.7 START-UP/SME EVALUATION MATRIX
10.7.1 PROGRESSIVE COMPANIES
10.7.2 RESPONSIVE COMPANIES
10.7.3 DYNAMIC COMPANIES
10.7.4 STARTING BLOCKS
FIGURE 32 START-UP/SME EVALUATION MATRIX, 2022
10.7.5 COMPETITIVE BENCHMARKING
TABLE 78 DETAILED LIST OF KEY START-UPS/SMES
10.8 COMPETITIVE SCENARIOS & TRENDS
11 COMPANY PROFILES
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
11.1.1 ADVANCED ACCELERATOR APPLICATIONS
TABLE 81 ADVANCED ACCELERATOR APPLICATIONS: COMPANY OVERVIEW
11.1.2 BAYER AG
TABLE 82 BAYER AG: COMPANY OVERVIEW
FIGURE 33 BAYER AG: COMPANY SNAPSHOT (2022)
11.1.3 GE HEALTHCARE
TABLE 83 GE HEALTHCARE: COMPANY OVERVIEW
FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022)
11.1.4 SIEMENS HEALTHINEERS AG
TABLE 84 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
11.1.5 CARDINAL HEALTH
TABLE 85 CARDINAL HEALTH: COMPANY OVERVIEW
FIGURE 36 CARDINAL HEALTH: COMPANY SNAPSHOT (2022)
11.1.6 PHILIPS HEALTHCARE
TABLE 86 PHILIPS HEALTHCARE: COMPANY OVERVIEW
FIGURE 37 PHILIPS HEALTHCARE: COMPANY SNAPSHOT (2022)
11.1.7 CANON INC.
TABLE 87 CANON INC.: COMPANY OVERVIEW
FIGURE 38 CANON INC.: COMPANY SNAPSHOT (2022)
11.1.8 CURIUM
TABLE 88 CURIUM: COMPANY OVERVIEW
11.1.9 LANTHEUS
TABLE 89 LANTHEUS: COMPANY OVERVIEW
FIGURE 39 LANTHEUS: COMPANY SNAPSHOT (2022)
11.1.10 NORTHSTAR MEDICAL RADIOISOTOPES
TABLE 90 NORTHSTAR MEDICAL RADIOISOTOPES: COMPANY OVERVIEW
11.1.11 ECKERT & ZIEGLER
TABLE 91 ECKERT & ZIEGLER: COMPANY OVERVIEW
FIGURE 40 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2022)
11.1.12 PHARMALOGIC
TABLE 92 PHARMALOGIC: COMPANY OVERVIEW
11.1.13 ECZACIBASI-MONROL
TABLE 93 ECZACIBASI-MONROL: COMPANY OVERVIEW
11.1.14 ACROTECH BIOPHARMA, INC.
TABLE 94 ACROTECH BIOPHARMA, INC.: COMPANY OVERVIEW
11.2 OTHER PLAYERS
11.2.1 THERMO FISHER SCIENTIFIC INC.
11.2.2 GLOBAL MEDICAL SOLUTIONS
11.2.3 SHINE TECHNOLOGIES, LLC
11.2.4 ISOTOPIA MOLECULAR IMAGING LTD.
11.2.5 INSTITUTE OF ISOTOPES
11.2.6 CHINA ISOTOPE & RADIATION CORPORATION
11.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD.
11.2.8 ATOMVIE
11.2.9 ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH
11.2.10 TELIX PHARMACEUTICALS LIMITED
11.2.11 BLUE EARTH DIAGNOSTICS
11.2.12 SOFIE BIOSCIENCES
11.2.13 THERAGNOSTICS
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
